The $2.5 Billion Question in Pharmaceutical Antitrust

In this episode, we examine the economic foundations of reverse-payment antitrust law through the lens of the Takeda verdict.The Supreme Court’s *Actavis* decision shifted the focus from patent validity to payment size—but left unresolved how courts should measure what counts as “large.”We explore the circularity embedded in the framework, the role of damages models, and why jury decisions may ultimately substitute for missing economic methods.Read the full article and the graphic analysis:https://blog.econworks.com/p/the-885-million-question-actavis?r=562wriExplore more visual economics content:EconWorksYouTubeSubstack This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit blog.econworks.com/subscribe